Prognostic factors in 1038 women with metastatic breast cancer

被引:292
作者
Largillier, R. [1 ]
Ferrero, J. -M. [1 ]
Doyen, J. [1 ]
Barriere, J. [1 ]
Namer, M. [1 ]
Mari, V. [1 ]
Courdi, A. [1 ]
Hannoun-Levi, J. M. [1 ]
Ettore, F. [1 ]
Birtwisle-Peyrottes, I. [1 ]
Balu-Maestro, C. [1 ]
Marcy, P. Y. [1 ]
Raoust, I. [1 ]
Lallement, M. [1 ]
Chamorey, E. [1 ]
机构
[1] Ctr Antoine Lacassagne, Dept Biostat & Epidemiol, F-06189 Nice 2, France
关键词
D O I
10.1093/annonc/mdn424
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Treatment of metastatic breast cancer (MBC) remains palliative. Patients with MBC represent a heterogeneous group whose prognosis and outcome may be dependent on host factors. The purpose of the present study was dual: first, to draw up a list of factors easily available in everyday clinical practice requiring no sophisticated or costly methods and second, to provide results from a large cohort of women who underwent diagnostic and treatment at a single institution. Patients and methods: From 1975 to 2005, a total of 1038 women with MBC during their follow-up were included in this retrospective analysis. Patients were subsequently assigned to five groups according to the period of metastatic diagnosis. Results: It is shown that age at initial diagnosis, hormonal receptor status and site of metastasis are the most relevant prognostic factors for predicting survival from the time of metastastic occurrence. It is also shown that a metastasis-free interval is an easily and immediately available multifactorial prognostic index reflecting the multiparametric variability of the disease. Conclusion: These fundamental observations may assist physicians in evaluating the survival potential of patients and in directing them toward the appropriate therapeutic decision.
引用
收藏
页码:2012 / 2019
页数:8
相关论文
共 28 条
[1]   Breast cancer with synchronous metastases: Trends in survival during a 14-year period [J].
Andre, F ;
Slimane, K ;
Bachelot, T ;
Dunant, A ;
Namer, M ;
Barrelier, A ;
Kabbaj, O ;
Spano, JP ;
Marsiglia, H ;
Rouzier, R ;
Delaloge, S ;
Spielmann, M .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3302-3308
[2]   Second consensus on medical treatment of metastatic breast cancer [J].
Beslija, S. ;
Bonneterre, J. ;
Burstein, H. ;
Cocquyt, V. ;
Gnant, M. ;
Goodwin, P. ;
Heinemann, V. ;
Jassem, J. ;
Koestler, W. J. ;
Krainer, M. ;
Menard, S. ;
Petit, T. ;
Petruzelka, L. ;
Possinger, K. ;
Schmid, P. ;
Stadtmauer, E. ;
Stockler, M. ;
Van Belle, S. ;
Vogel, C. ;
Wilcken, N. ;
Wiltschke, C. ;
Zielinski, C. C. ;
Zwierzina, H. .
ANNALS OF ONCOLOGY, 2007, 18 (02) :215-225
[3]   COMPARISON OF LIGAND-BINDING ASSAY AND ENZYME-IMMUNOASSAY OF ESTROGEN-RECEPTOR IN HUMAN BREAST-CANCER CYTOSOLS - EXPERIENCE OF THE EORTC RECEPTOR GROUP [J].
BLANKENSTEIN, MA .
BREAST CANCER RESEARCH AND TREATMENT, 1990, 17 (02) :91-98
[4]   HISTOLOGICAL GRADING AND PROGNOSIS IN BREAST CANCER - A STUDY OF 1409 CASES OF WHICH 359 HAVE BEEN FOLLOWED FOR 15 YEARS [J].
BLOOM, HJG ;
RICHARDSON, WW .
BRITISH JOURNAL OF CANCER, 1957, 11 (03) :359-&
[5]   Survival of patients with metastatic breast carcinoma - Importance of prognostic markers of the primary tumor [J].
Chang, J ;
Clark, GM ;
Allred, DC ;
Mohsin, S ;
Chamness, G ;
Elledge, RM .
CANCER, 2003, 97 (03) :545-553
[6]   SURVIVAL FROM 1ST RECURRENCE - RELATIVE IMPORTANCE OF PROGNOSTIC FACTORS IN 1,015 BREAST-CANCER PATIENTS [J].
CLARK, GM ;
SLEDGE, GW ;
OSBORNE, CK ;
MCGUIRE, WL .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (01) :55-61
[7]   Clinical course and prognostic factors following bone recurrence from breast cancer [J].
Coleman, RE ;
Smith, P ;
Rubens, RD .
BRITISH JOURNAL OF CANCER, 1998, 77 (02) :336-340
[8]  
CUTLER SJ, 1969, CANCER-AM CANCER SOC, V24, P861, DOI 10.1002/1097-0142(196911)24:5<861::AID-CNCR2820240502>3.0.CO
[9]  
2-3
[10]   AGE AS PROGNOSTIC FACTOR IN PREMENOPAUSAL BREAST-CARCINOMA [J].
DELAROCHEFORDIERE, A ;
ASSELAIN, B ;
CAMPANA, F ;
SCHOLL, SM ;
FENTON, J ;
VILCOQ, JR ;
DURAND, JC ;
POUILLART, P ;
MAGDELENAT, H ;
FOURQUET, A .
LANCET, 1993, 341 (8852) :1039-1043